MAFLD comprises a wide range of liver injury, from simple steatosis to steatohepatitis, progressive fibrosis and eventually cirrhosis with its complications, including portal hypertension and HCC.
Besides MRI and liver biopsy, ultrasound offers strong benefits for liver fat quantification as it is a non-invasive, low risks, easy to access and low-cost.
The description of the new Ultrasound Derived Fat Fraction technology (UDFF) is made in this presentation. Its accuracy and strong agreement with the MRI-PDFF technic are shown. Some case studies illustrate the benefits of the use of UDFF combined with liver stiffness measurement to predict the probability of MASH on MAFLD patients.